GLP-1 maintenance after weight loss: what the science says

What did @obesitydrdannak actually say?

The creator, who presents as an obesity medicine physician, argued that GLP-1 medications are "chronic treatments" because obesity is a chronic disease, and that patients should not stop simply because they hit a goal weight. She described her maintenance approach as trialing patients on lower doses and monitoring their response, while acknowledging that some people will need to stay at the highest dose indefinitely. She also said that feeling some hunger during maintenance is "a healthy physiologic response" but that "uncontrollable hunger" is the red flag worth addressing.

She was responding to a user question, which gives the advice a personal, conversational framing. None of this was presented as a protocol, more as a philosophy. That context matters when you start pulling it apart.

Does the science back this up?

Yes, largely. The evidence that obesity requires ongoing treatment rather than a short course is genuinely robust, and the regain data after stopping GLP-1s is hard to argue with.

The STEP 4 trial (Rubino et al., 2021, JAMA) is probably the most cited data point here. Participants who stopped semaglutide after 20 weeks regained, on average, two-thirds of their lost weight within a year. A 2022 follow-up analysis of tirzepatide (SURMOUNT-4, Aronne et al., 2024, JAMA) showed similar regain patterns after discontinuation. These findings support the "chronic treatment" framing pretty directly.

The dose-reduction idea for maintenance is less settled. There is no large, randomized trial comparing maintenance at maximum dose versus a lower titrated dose over the long term. The creator is describing clinical practice, not a validated protocol. That is worth knowing.

What did they get wrong (or right)?

She got the core framing right. Calling obesity a chronic disease is consistent with positions from the American Academy of Obesity Medicine, the Obesity Society, and a substantial body of metabolic research. Framing GLP-1 discontinuation as likely to cause regain is also accurate based on available evidence.

Where things get murkier is the dose-tapering advice. She frames it as an experiment, which is honest, but the implication that a lower dose will work for some people in maintenance is speculative at this point. There is no validated dose-reduction protocol for semaglutide or tirzepatide maintenance published in peer-reviewed literature. The FDA-approved maintenance dose for Wegovy is 2.4 mg weekly, and for Zepbound it is 10 mg or 15 mg weekly. Suggesting that lower doses might maintain weight loss for some patients is a reasonable clinical hypothesis, but it should not be mistaken for established guidance.

Her point about food "noise" and cognitive clarity after starting GLP-1s is well-supported anecdotally and increasingly in the literature. Blundell et al. (2017, Diabetes, Obesity and Metabolism) documented reduced hedonic hunger with liraglutide, and similar findings have emerged with semaglutide.

What should you actually know?

Three things are worth holding onto here. First, the regain-after-stopping data is real. If you are considering stopping a GLP-1 after hitting a goal weight, the probability of regain is high based on current evidence. That does not mean you must stay on it forever, but it is a risk you should understand and discuss with a prescribing clinician.

Second, dose adjustments during maintenance are not a standardized practice. A physician experimenting with lower doses is not doing anything reckless, but it is not evidence-based in a formal sense. Your response may differ from the next patient's.

Third, "pausing" a GLP-1, which the creator mentions as an option, is understudied. There are no published trials on intermittent GLP-1 use for weight maintenance. Anyone describing it as a low-risk strategy is extrapolating beyond the data we have.

Bottom line

This is one of the more medically grounded TikToks you will see in the GLP-1 space. The creator avoids making cure claims, does not prescribe specific doses, and is transparent that her approach involves clinical judgment rather than a fixed protocol. The chronic-disease framing is well-supported. The dose-tapering approach is reasonable but speculative, and viewers should understand the difference. If you are managing GLP-1 maintenance, the most important step is working with a clinician who is tracking your actual response, not following a one-size approach in either direction.